{
    "id": 1784,
    "fullName": "ROS1 positive",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "ROS1 positive indicates the presence of the ROS1 gene, mRNA, and/or protein. ROS1 positive has been used alternatively to refer to presence of a ROS1 fusion or rearrangement. For related data, refer to ROS1 fusion or ROS1 rearrange in CKB.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 6098,
        "geneSymbol": "ROS1",
        "terms": [
            "ROS1",
            "c-ros-1",
            "MCF3",
            "ROS"
        ]
    },
    "variant": "positive",
    "createDate": "09/18/2014",
    "updateDate": "06/24/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 10351,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Rozlytrek (entrectinib) treatment resulted in stable disease in a patient with ROS1-positive pancreatic cancer (J Clin Oncol 32:5s, 2014 (suppl; abstr 2502)).",
            "molecularProfile": {
                "id": 1771,
                "profileName": "ROS1 positive"
            },
            "therapy": {
                "id": 1455,
                "therapyName": "Entrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8339,
                    "pubMedId": null,
                    "title": "Phase 1 open label, dose escalation study of RXDX101, an oral pan-trk, ROS1, and ALK inhibitor, in patients with advanced solid tumors with relevant molecular alterations.",
                    "url": "http://meetinglibrary.asco.org/content/131059-144"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18117,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a combined analysis of 3 clinical trials (ALKA-372-001, STARTRK-1, STARTRK-2) that supported FDA approval, Rozlytrek (entrectinib) treatment resulted in an objective response rate of 77% (41/53), a median duration of response of 25 months in patients with ROS1 fusion positive non-small cell lung cancer, with median progression-free survival of 26 and 14 months for patients without (n=30) and with (n=23) CNS disease, respectively (Cancer Res 2019;79(13 Suppl):Abstract nr CT192; NCT02097810; NCT02568267).",
            "molecularProfile": {
                "id": 1771,
                "profileName": "ROS1 positive"
            },
            "therapy": {
                "id": 1455,
                "therapyName": "Entrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16003,
                    "pubMedId": null,
                    "title": "Rozlytrek (entrectinib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212725"
                },
                {
                    "id": 16004,
                    "pubMedId": null,
                    "title": "Entrectinib in locally advanced or metastatic ROS1 fusion-positive non-small cell lung cancer (NSCLC): Integrated analysis of ALKA-372-001, STARTRK-1 and STARTRK-2",
                    "url": "https://cancerres.aacrjournals.org/content/79/13_Supplement/CT192"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        }
    ],
    "molecularProfiles": [
        {
            "id": 1771,
            "profileName": "ROS1 positive",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 24174,
            "profileName": "ALK neg ROS1 pos",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}